

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/280,020
				Filing Date	March 29, 1999
				First Named Inventor	Dupre
				Group Art Unit	1644
				Examiner Name	Nolan, P.
Sheet	1	of	5	Attorney Docket Number	030639.0034.RCE2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
PN ↓	AA	5,118,666		Habener	06-02-1992	
	AB	5,120,712		Habener	06-09-1992	
	AC	5,234,906		Young, et al.	08-10-1993	
	AD	5,424,286		Eng	06-13-1995	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
PN ↓	AE	AU	40275/93	B	Pfizer Inc.	01-04-1994		
	AF	AU	55016/94	B	Scios Inc.	10-13-1994		
	AG	AU	91883/82	A	Novo Industri A/S	06-30-1983		
	AH	EP	0 044 168	B1	Novo Industri A/S	05-22-1985		
	AI	EP	0 869 135	A1	Eli Lilly and Company	10-07-1998		
	AJ	WO	90/11296		The General Hospital Corporation	10-04-1990		
	AK	WO	91/11457		Buckley, Douglas I. et al.	08-08-1991		
	AL	WO	93/18786		Novo Nordisk A/S	09-30-1993		
	AM	WO	93/25579		Pfizer Inc.	12-23-1993		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
PN	AN	ANDREWS, <i>et al.</i> , "Isolation and structures of Glucagon and Glucagon-like peptide from catfish pancreas," <i>Journal of Biological Chemistry</i> , 260(7):3910-3914 (1985)			
↓	AO	BELL, <i>et al.</i> , "Hamster preproglucagon contains the sequence of glucagon and two related peptides," <i>Nature</i> , 302(21):716-718 (1983)			
	AP	CHOU, <i>et al.</i> , "A Radioimmunoassay for LY315902, an Analog of Glucagon-Like Insulinotropic Peptide, and Its Application in the Study of Canine Pharmacokinetics," <i>J. Pharm. Sci.</i> , 86(7):768-773 (1997)			
	AQ	CREUTZFELDT, "Entero-Insular Axis and Diabetes Mellitus," <i>Horm. Metab. Res. Suppl.</i> , 26:13-18 (1992)			
	AR	CRYER, <i>et al.</i> , "Hypoglycemia in IDDM," <i>Diabetes</i> , 38:1193-9 (1989)			



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
		Application Number	09/280,020
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	March 29, 1999
		First Named Inventor	Dupre
		Group Art Unit	1644
		Examiner Name	Nolan, P.
		Attorney Docket Number	030639.0034.RCE2
Sheet	2	of	5

PN	AS	D'ALESSIO, <i>et al.</i> , "Glucagon-like Peptide 1 Enhances Glucose Tolerance Both by Stimulation of Insulin Release and by Increasing Insulin-independent Glucose Disposal," <i>J. Clin. Invest.</i> , 93:2263-2266 (1994)	
	AT	DONAHUE, <i>et al.</i> , "Postchallenge Glucose Concentration and Coronary Heart Disease in Men of Japanese Ancestry," <i>Diabetes</i> , 36:689-692 (1987)	
	AU	DUPRE, <i>et al.</i> , "Insulinotropic Effect of Glucagon-Like Peptide I (7-36) Amide in C-Peptide-Positive Type I Diabetes Mellitus," Abstract 221, Page B38, <i>Clinical and Investigative Medicine</i> (1994)	
	AV	EGAN, <i>et al.</i> , "Glucagon-like Peptide-1 (7-36) Amide (GLP-1) Enhances Insulin-Stimulated Glucose Metabolism in 3T3-L1 Adipocytes: One of Several Potential Extraparacrine Sites of GLP-1 Action," <i>Endocrinology</i> , 135(5):2070-2075 (1994)	
	AW	FERRANNINI, <i>et al.</i> , "The Disposal of an Oral Glucose Load in Healthy Subjects: A Quantitative Study," <i>Diabetes</i> , 34:580-588 (1985)	
	AX	FERRANNINI, <i>et al.</i> , "The Disposal of an Oral Glucose Load in Patients with Non-Insulin-Dependent Diabetes," <i>Metabolism</i> , 37(1):79-85 (1988)	
	AY	FRASER, <i>et al.</i> , "Hyperglycaemia Slows Gastric Emptying in Type 1 (Insulin-Dependent) Diabetes Mellitus," <i>Diabetologia</i> , 33:675-680 (1990)	
	AZ	FULLER, <i>et al.</i> , "Coronary-Heart-Disease Risk and Impaired Glucose Tolerance," <i>The Lancet</i> , 1373-1376 (1980)	
	BA	GERICH, <i>et al.</i> , "Prevention of Human Diabetic Ketoacidosis by Somatostatin," <i>New England J. Med.</i> , 292(19):985-999 (1975)	
	BB	GHIGLIONE, <i>et al.</i> , "How Glucagon-Like is Glucagon-Like peptide-1?" <i>Diabetologia</i> 27:599-600 (1984)	
	BC	GROMADA, <i>et al.</i> , "Glucagon-Like Peptide 1(7-36) Amide Stimulates Exocytosis in Human Pancreatic β -Cells by Both Proximal and Distal Regulatory Steps in Stimulus-Secretion Coupling," <i>Diabetes</i> , 47:57-65 (1998)	
	BD	GUTNIAK, <i>et al.</i> , "Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus," <i>New England Journal of Medicine</i> , 326(20):1316-1322 (1992)	
	BE	GUTNIAK, <i>et al.</i> , "Glucagon-Like Insulinotropic Peptide 1 (7-36) – New Approach to Treating Diabetes?," <i>Diabetologia</i> , (Published from the 26 th Annual Meeting of the European Association for the Study of Diabetes), 33(Supp.):A73 (1990)	
	BF	HARGROVE, <i>et al.</i> , "Comparison of the Glucose Dependency of Glucagon-Like Peptide-1(7-37) and Glyburide In Vitro and In Vivo," <i>Metabolism</i> , 45(3):404-409 (1996)	
	BG	HARGROVE, <i>et al.</i> , "Glucose-Dependent Action of Glucagon-Like Peptide-1(7-37) In Vivo During Short- or Long-Term Administration," <i>Metabolism</i> , 44(9):1231-1237	
	BH	HENDRICK, <i>et al.</i> , "Glucagon-like Peptide 1 (7-37) Blunts Postprandial Glycaemic Excursion in Rats with Mild Diabetes," <i>Diabetologia</i> , 32(7):496A (1989) (Abstract)	
✓	BI	HENDRICK, <i>et al.</i> , "Glucagon-like Peptide-1-(7-37) Suppresses Hyperglycemia in Rats," <i>Metabolism</i> , 42(1):1-6 (1993)	



Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/280,020
		Filing Date	March 29, 1999
		First Named Inventor	Dupre
		Group Art Unit	1644
		Examiner Name	Nolan, P.
		Attorney Docket Number	030639.0034.RCE2
Sheet	3	of	5

RECEIVED
OCT 02 2002
TECH CENTER 1600/2900

PN	BJ	HOLST, "Glucagon Peptide 1: A Newly Discovered Gastrointestinal Hormone," <i>Gastroenterology</i> , 107(6):1848-1855 (1994) (Abstract)	
	BK	HOROWITZ, <i>et al.</i> , "Disordered Gastric Motor Function in Diabetes Mellitus," <i>Diabetologia</i> , 37:543-551 (1994)	
	BL	HOROWITZ, <i>et al.</i> , "Effects of Diabetes Mellitus on Gastrointestinal Motor Function," <i>Neuroscience Research Comm.</i> , 21(1):75-82 (1997)	
	BM	HOROWITZ, <i>et al.</i> , "Gastrointestinal Motor Function in Diabetes Mellitus: Relationship to Blood Glucose Concentration," <i>J. Gastro. Hep.</i> 13(Supp.):S239-S245 (1998)	
	BN	HOROWITZ, <i>et al.</i> , "Gastric Emptying in Diabetes: An Overview," <i>Diabet. Med.</i> , 13(9 Supp. 5):S16-22 (Abstract) (1996)	
	BO	HOROWITZ, <i>et al.</i> , "Gastroparesis: Diagnosis and Management," <i>Scand. J. Gastroenterol. Suppl.</i> , 213:7-16 (Abstract) (1995)	
	BP	HOROWITZ, <i>et al.</i> , "Relationship Between Oesophageal Transit and Solid and Liquid Gastric Emptying in Diabetes Mellitus," <i>Eur. J. Nucl. Med.</i> , 18:229-234 (1991)	
	BQ	HOROWITZ, <i>et al.</i> , "Relationship Between Oral Glucose Tolerance and Gastric Emptying in Normal Healthy Subjects," <i>Diabetologia</i> , 36:857-862 (1993)	
	BR	HVIDBERG, <i>et al.</i> , "Effect of Glucagon-like Peptide-1 (Proglucagon 78-107 Amide) on Hepatic Glucose Production in Healthy Man," <i>J. Metabolism</i> , 43(1):104-108 (1994)	
	BS	JACKSON, <i>et al.</i> , "A Comparison of the Relationships of the Glucose Tolerance Test and the Glycated Haemoglobin Assay with Diabetic Vascular Disease in the Community," <i>Diabetes Res. and Clin. Prac.</i> , 17:111-123 (1992)	
	BT	KNUDSEN, <i>et al.</i> , "Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration," <i>J. Med. Chem.</i> , 43(9):1664-1669 (2000)	
	BU	KONG, <i>et al.</i> , "Natural History of Diabetic Gastroparesis," <i>Diabetes Care</i> , 22(3):503-507 (1999)	
	BV	KREYMANN, <i>et al.</i> , "Glucagon-like Peptide-1 7-36 Amide, A New Brain-Gut Hormone and Its Effect on Pancreatic Endocrine Function in Man," <i>Biomed. Res.</i> 9(Supp. 3):207-211 (1988)	
	BW	KREYMANN, <i>et al.</i> , "Glucagon-like Peptide-1 7-36: A Physiological Incretin in Man," <i>Lancet</i> , 2:1300-1304 (1987)	
	BX	KUMAR, <i>et al.</i> , "Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties: T-cell activation, major histocompatibility complex binding, and ability to block experimental allergic encephalomyelitis," <i>Proc. Natl. Acad. Sci.</i> , 87:1337-1341 (1990)	
	BY	LARSEN, <i>et al.</i> , "Glucagon-Like Peptide-1 Infusion Must Be Maintained for 24 h/day to Obtain Acceptable Glycemia in Type 2 Diabetic Patients Who Are Poorly Controlled on Sulphonylurea Treatment," <i>Diabetes Care</i> , 24(8):1416-1421 (2001)	
✓	BZ	MOUROT, <i>et al.</i> , "Relationship Between the Rate of Gastric Emptying and Glucose and Insulin Responses to Starchy Foods in Young Healthy Adults," <i>Am. J. Clin. Nutr.</i> , 48:1035-1040 (1988)	



Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/280,020
		Filing Date	March 29, 1999
		First Named Inventor	Dupre
		Group Art Unit	1644
		Examiner Name	Nolan, P.
		Attorney Docket Number	030639.0034.RCE
Sheet	4	of	5

RECEIVED

OCT 02 2002

TECH CENTER 1600/2900

PN	CA	NANKERVIS, <i>et al.</i> , "Impaired Insulin Action in Newly Diagnosed Type 1 (Insulin-Dependent) Diabetes Mellitus," <i>Diabetologia</i> , 27(5):497-503 (Abstract) (1984)	
	CB	NATHAN, <i>et al.</i> , "Insulinotropic Action of Glucagonlike Peptide-1-(7-37) in Diabetic and Nondiabetic Subjects," <i>Diabetes Care</i> , 15:270-276 (1992)	
	CC	NAUCK, <i>et al.</i> , "Additive Insulinotropic Effects of Exogenous Synthetic Human Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 (7-36) Amide Infused at Near-Physiological Insulinotropic Hormone and Glucose Concentrations," <i>JCE & M</i> , 76(4):912-917 (1993)	
	CD	NAUCK, <i>et al.</i> , "Preserved Incretin Activity of Glucagon-like Peptide 1 [7-36 Amide] but Not of Synthetic Human Gastric Inhibitory Polypeptide in Patients with Type-2 Diabetes Mellitus," <i>J. Clin. Invest.</i> , 91:301-307 (1993)	
	CE	NGO, in <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz (ed), Birkhauser Boston, pp 492-495 (1992)	
	CF	PROIETTO, <i>et al.</i> , "Glucose Utilization in Type 1 (Insulin-Dependent) Diabetes: Evidence for a Defect not Reversible by Acute Elevations of Insulin," <i>Diabetologia</i> , 25(4):331-5 (Abstract) (1983)	
	CG	RAYNER, "Relationships of Upper Gastrointestinal Motor and Sensory Function With Glycemic Control," <i>Diabetes Care</i> , 24(2):371-394 (2001)	
	CH	SCHMIDT, "Glucagon-Like peptide-1 but not Glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets," <i>Diabetologia</i> , 28:704-707 (1985)	
	CI	SCHVARCZ, <i>et al.</i> , "Hypoglycaemia Increases the Gastric Emptying Rate in Patients with Type 1 Diabetes Mellitus," <i>Diabetic Medicine</i> , 10:660-663 (1993)	
	CJ	SCHVARCZ, <i>et al.</i> , "Physiological Hyperglycemia Slows Gastric Emptying in Normal Subjects and Patients with Insulin-Dependent Diabetes Mellitus," <i>Gastroenterology</i> , 113:60-66 (1997)	
	CK	SCHWARTZ, <i>et al.</i> , "Treatment With an Oral Proteinase Inhibitor Slow Gastric Emptying and Acutely Reduces Glucose and Insulin Levels After a Liquid Meal in Type II Diabetic Patients," <i>Diabetes Care</i> , 17(4):255-262 (1994)	
	CL	STEVENSON, <i>et al.</i> , "Role of Glucagon Suppression on Gluconeogenesis During Insulin Treatment of the Conscious Diabetic Dog," <i>Diabetologia</i> , 30:782-90 (1987)	
	CM	THOMPSON, <i>et al.</i> , "Gastric Emptying as a Determinant of the Oral Glucose Tolerance Test," <i>Gastroenterology</i> , 82:51-55 (1982)	
	CN	TORSODOTTIR, <i>et al.</i> , "Effect of Different Starchy Foods in Composite Meals on Gastric Emptying Rate and Glucose Metabolism," <i>Human Nutrition: Clinical Nutrition</i> , 38C:329-338 (1984)	
	CO	TURTLE, <i>et al.</i> , (Ed.), "Acarbose," <i>Diabetes in the New Millennium</i> , Ch. 21, pp. 213-5 (The Endocrinology and Diabetes Research Foundation of the University of Sydney: 1999)	
	CP	UNGER, "Role of Glucagon in the Pathogenesis of Diabetes: The Status of the Controversy," <i>Metabolism</i> , 27(11):1691-1709 (1978)	
✓	CQ	VILLANUEVA-PENACARRILLO, <i>et al.</i> , "Increased Glucagon-like Peptide 1 (7-36) Amide Binding in Adipose Tissue from Non-Insulin Dependent and Insulin-Dependent Diabetic Patients," <i>Diabetes Nutr. Metab. Clin. Exp.</i> , 7(3):143-148 (1994)	

PTO
SEP 30 2002
PATENT & TRADEMARK

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/280,020
		Filing Date	March 29, 1999
		First Named Inventor	Dupre
		Group Art Unit	1644
		Examiner Name	Nolan, P.
		Attorney Docket Number	030639.0034.RCE2
Sheet	5	of	5

PN	CR	WETTERGREN, <i>et al.</i> , "Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man," <i>Digestive Diseases and Sciences</i> , 38(4):665-673 (1993)
----	----	--

Examiner Signature	<i>Peter J. Noz</i>	Date Considered	12/3/02
--------------------	---------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
OCT 2 2002
TECH CENTER
1600/2900

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 09/280,020
Filing Date March 29, 1999
First Named Inventor Dupre
Group Art Unit 1644
Examiner Name Nolan, P.
Attorney Docket Number 030639.0034.RCE2

RECEIVED

OCT 25 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
PN	CS	EP	0 708 179	A3	Eli Lilly and Company	08-28-1996	
PN	CT	GB	94 09496.8	B	London Health Association	05-12-1994	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PN	CU	FEHMANN, <i>et al.</i> , "Insulinotropic Hormone Glucagon-like Peptide-1(7-37) Stimulation of Proinsulin Gene Expression and Proinsulin Biosynthesis in Insulinoma Beta TC-1 Cells," <i>Endocrinology</i> , 130(1):159-66 (1992)	
	CV	GROMADA, <i>et al.</i> , "Desensitization of Glucagon-like Peptide 1 Receptors in Insulin-secreting β TC3 Cells: Role of PKA-independent Mechanisms," <i>Brit. Jour. Phar.</i> , 118:769-75 (1996)	
	CW	GROMADA, <i>et al.</i> , "Cellular Regulation of Islet Hormone Secretion by the Incretin Hormone Glucagon-like Peptide 1," <i>Eur. J. Physiol.</i> , 435:583-94 (1998)	
	CX	JONES, <i>et al.</i> , "Effects of Fedotozine on Gastric Emptying and Upper Gastrointestinal Symptoms in Diabetic Gastroparesis," <i>Ailment. Pharmacol. Ther.</i> , 14:937-43 (2000)	

Examiner Signature *Pat JNR*

Date Considered

12/30/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
Application Number		09/280,020	
Filing Date		March 29, 1999	
First Named Inventor		Dupre	
Group Art Unit		1644	
Examiner Name		Nolan, P.	
Attorney Docket Number		030639.0034.RCE2	

Sheet 1 of 1

RECEIVED OCT 25 2002 TECH CENTER 600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ² (if known)			
PN	CS	EP	0 708 179	A3	Eli Lilly and Company	08-28-1996	
PN	CT	GB	94 09496.8	B	London Health Association	05-12-1994	

RECEIVED NOV 13 2002 TECH CENTER 600/2900

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
PN	CU	FEHMANN, et al., "Insulinotropic Hormone Glucagon-like Peptide-1(7-37) Stimulation of Proinsulin Gene Expression and Proinsulin Biosynthesis in Insulinoma Beta TC-1 Cells," <i>Endocrinology</i> , 130(1):159-66 (1992)	
	CV	GROMADA, et al., "Desensitization of Glucagon-like Peptide 1 Receptors in Insulin-secreting βTC3 Cells: Role of PKA-independent Mechanisms," <i>Brit. Jour. Phar.</i> , 118:769-75 (1996)	
	CW	GROMADA, et al., "Cellular Regulation of Islet Hormone Secretion by the Incretin Hormone Glucagon-like Peptide 1," <i>Eur. J. Physiol.</i> , 435:583-94 (1998)	
	CX	JONES, et al., "Effects of Fedotozine on Gastric Emptying and Upper Gastrointestinal Symptoms in Diabetic Gastroparesis," <i>Ailment. Pharmacol. Ther.</i> , 14:937-43 (2000)	

Examiner Signature	<i>Patricia L. NDR</i>	Date Considered	12/30/02
--------------------	------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark